NCT06803589EARLY_PHASE1Recruiting
Growth Hormone for the Treatment of Gastroparesis
Mayo Clinic
Start Date
10/22/2024
Completion Date
12/1/2027
Summary
The purpose of this study is to determine whether treatment with Growth Hormone results in symptomatic improvement in patients with gastroparesis.
Eligibility Criteria
Age Range: 18 years to 65 years
Inclusion Criteria:
* Symptoms \> 6 months that have not responded satisfactorily to standard treatment.
* For gastroparesis: Gastroparesis Cardinal Symptom Index (GCSI) score of \>21
Exclusion Criteria:
* Known history of GH deficiency, hypothalamic or pituitary disease
* Diabetes
* Prior use of GH therapy
* Age-adjusted low serum IGF1
* Women on oral estrogen therapy6
* Pregnancy or nursing
* History of malignant solid tumors
* Obesity (BMI \> 30)History of coronary and thromboembolic diseases.
* History of sarcoidosis
* History of pituitary surgery
* History of thyroid nodules.
* Any other condition, which in the opinion of the investigator would impede compliance or hinder completion of the study.
* Failure to give informed consent.
Interventions
DRUG
Growth Hormone
Conditions
Gastroparesis
Locations
Mayo Clinic
Phoenix, Arizona 85054
United States
Mayo Clinic in Arizona
Scottsdale, Arizona 85259
United States